(19)

(11)

EP 3 116 877 A1

(12)

(43) Date of publication: 18.01.2017 Bulletin 2017/03 (21) Application number: 15714943.6 (22) Date of filing: 11.03.2015

(51) International Patent Classification (IPC):  C07D 487/04(2006.01) A61K 31/519(2006.01) A61P 35/00(2006.01) A61P 25/28(2006.01) A61K 31/4365(2006.01) C07D 495/04(2006.01) A61P 25/16(2006.01) (86) International application number: PCT/IB2015/051774 (87) International publication number: WO 2015/136463 (17.09.2015 Gazette 2015/37)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: MA (30) Priority: 11.03.2014 US 201461951109 P (71) Applicant: GlaxoSmithKline Intellectual Property (No. 2) Limited Brentford, Middlesex TW8 9GS (GB)	(72) Inventors: AXTEN, Jeffrey M. King of Prussia, Pennsylvania 19406 (US) MEDINA, Jesus Raul Collegeville, Pennsylvania 19426 (US) (74) Representative: Reed, Michael Antony  GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS Brentford, Middlesex TW8 9GS (GB)